Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.
- Published In:
- Genes & diseases, 12(6), 101761 (2025)
- Authors:
- Li, Yun(2), Sun, Wencong, Liu, Hong, Ruan, Xiong Z
- Database ID:
- RPEP-12134
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12134APA
Li, Yun; Sun, Wencong; Liu, Hong; Ruan, Xiong Z. (2025). Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.. Genes & diseases, 12(6), 101761. https://doi.org/10.1016/j.gendis.2025.101761
MLA
Li, Yun, et al. "Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates metabolic dysfunction-associated steatotic liver disease by reducing the expression of CD36 and OBP2A.." Genes & diseases, 2025. https://doi.org/10.1016/j.gendis.2025.101761
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide, a dual GIP/GLP-1 receptor agonist, alleviates m..." RPEP-12134. Retrieved from https://rethinkpeptides.com/research/li-2025-tirzepatide-a-dual-gipglp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.